NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Elisa Chazeau und 6 weiteren Autor:innen. Beteiligte Einrichtung: ICMUB, UMR 6302 CNRS, Université Bourgogne Europe, 9 av. A. Savary, BP 47870, 21078 Dijon, France. Hauptthemen laut MEDLINE: Immunoconjugates, Boron Compounds, Fluorescent Dyes, Trastuzumab. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, Ligue Contre le Cancer, Centre National de la Recherche Scientifique.
Abstract (Originalsprache)
Real-time imaging of antibody-drug conjugates (ADCs) offers valuable insights for assessing tumor targeting specificity, monitoring therapeutic efficacy, and detecting off-target accumulation that may cause adverse effects. To enable precise tracking, we developed a versatile fluorescent platform based on an NIR-II emitting aza-BODIPY dye, which can be site-specifically grafted onto an IgG1 antibody to generate well-defined fluorescent ADCs. As a proof of concept, we synthesized an HER2-targeting trastuzumab immunoconjugate bearing a NIR-II aza-BODIPY fluorophore. The cytotoxic monomethyl auristatin E (MMAE) payload was introduced in the final step, resulting in a trackable and homogeneous ADC suitable for both in vitro and in vivo investigations. The resulting Trastu-azaNIRII-MMAE selectively accumulated in HER2-positive subcutaneous tumors, significantly reducing the tumor growth. Using NIR-II optical imaging, a single injection of the NIR-II-ADC allowed for the detection of the conjugate over a period of more than one month, highlighting its potential for long-term tracking and therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ICMUB, UMR 6302 CNRS, Université Bourgogne Europe, 9 av. A. Savary, BP 47870, 21078 Dijon, France.
- Laboratoire d'Immunologie et Immunothérapie des Cancers, EPHE, PSL Research University, 75000 Paris, France.
- CTM, UMR1231 INSERM, Université de Bourgogne, 21000 Dijon, France.
- Division Biophotonics, Federal Institute for Materials Research and Testing (BAM), 12489 Berlin, Germany.
- Plateforme de Transfert en Biologie Cancérologique, CGFL, 21000 Dijon, France.
- Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France.
ORCID-Profile: K David Wegner, Lucie Sancey, Catherine Paul, Christine Goze
Förderung
- Agence Nationale de la Recherche
- Ligue Contre le Cancer
- Centre National de la Recherche Scientifique
- Minist?re de l'Enseignement sup?rieur et de la Recherche
- Conseil r?gional de Bourgogne-Franche-Comt?
- Comit? de C?te d?Or and Comit? de l?Is?re
Zitieren
APA
Chazeau, E., Pipier, A., Wegner, K. D., Ghiringhelli, F., Sancey, L., Paul, C., & Goze, C. (2025). NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02777
Vancouver
Chazeau E, Pipier A, Wegner KD, Ghiringhelli F, Sancey L, Paul C, et al. NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02777
BibTeX
@article{Chazeau2025,
author = {Chazeau, Elisa and Pipier, Angélique and Wegner, K David and Ghiringhelli, François and Sancey, Lucie and Paul, Catherine and Goze, Christine},
title = {NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02777}
}
EUVIMED